松龄血脉康胶囊联合苯磺酸氨氯地平对肝阳上亢型高血压病人血浆MDA、NOS、SOD活性及血压变异性的影响  

Effects of Songling Xuemaikang Capsule and Amlodipine Besylate on Plasma MDA,NOS,SOD Activity and Blood Pressure Variability in Hypertensive Patients with Liver-yang Hyperactivity Syndrome

作　　者：于艳 YU Yan(General Hospital of Shenma,Shenma Medical Group,Pingdingshan 467000,Henan,China)

机构地区：[1]平煤神马医疗集团总医院,河南平顶山467000

出　　处：《中西医结合心脑血管病杂志》2019年第7期986-989,共4页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：河南省医学科技攻关计划项目(No.201603021)

摘　　要：目的观察松龄血脉康胶囊联合苯磺酸氨氯地平对肝阳上亢型高血压病人血浆丙二醛(MDA)、一氧化氮合酶(NOS)、超氧化物歧化酶(SOD)活性及血压变异性(BPV)的影响。方法将94例肝阳上亢型高血压病人按照随机数字表法分为观察组与对照组,各47例。对照组给予苯磺酸氨氯地平治疗,观察组在对照组基础上加用松龄血脉康胶囊治疗,两组均持续治疗4周。观察两组临床疗效、中医证候积分、血浆MDA、NOS、SOD活性、血压及血压变异性,比较两组不良反应。结果观察组总有效率为97.87%,显著高于对照组的82.98%(P<0.05);治疗后,两组中医证候积分均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);治疗后,两组血浆MDA水平显著降低(P<0.05),血浆NOS、SOD活性显著升高(P<0.05),且观察组显著优于对照组(P<0.05);治疗后,两组24 h平均收缩压(24 h SBP)、24 h平均舒张压(24 h DBP)、24 h平均收缩压变异性(24 h SBPV)、24 h平均舒张压变异性(24 h DBPV)均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论松龄血脉康胶囊联合苯磺酸氨氯地平治疗肝阳上亢型高血压,可改善血浆MDA、NOS、SOD活性,降低BPV。Objective To investigate the effects of Songling Xuemaikang capsule(SXC) and amlodipine besylate on plasma malondialdehyde(MDA),nitric oxide synthase(NOS),superoxide dismutase(SOD) activities and blood pressure variability(BPV) in hypertensive patients with liver-yang hyperactivity syndrome. Methods Ninety-four hypertensive patients with liver-yang hyperactivity syndrome were randomly divided into two groups:control group( n =47) treated with amlodipine besylate,and observation group( n =47) treated with SXC and amlodipine besylate for 4 weeks.The clinical efficacy,traditional Chinese medicine(TCM) syndrome score,plasma MDA,NOS,SOD activities,blood pressure, and BPV were observed.The adverse reactions were compared between the two groups. Results The total effective rate was significantly higher in observation group than that in control group(97.87% vs.82.98%, P <0.05).After treatment,TCM syndromes scores and plasma MDA levels were significantly lower in two groups( P <0.05),which was significantly lower in the observation group than that in the control group( P <0.05).After treatment,plasma NOS,SOD activities levels in two groups were significantly higher( P <0.05),which was significantly higher in the observation group than that in the control group( P <0.05).After treatment,24 h average systolic blood pressure(24 h SBP),24 h average diastolic blood pressure(24 h DBP),24 h average systolic BPV(24 h SBPV),24 h average diastolic BPV(24 h DBPV) were significantly lower in two groups( P <0.05),which was significantly lower in the observation group than that in the control group( P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups( P >0.05). Conclusion SXC and amlodipine besylate can improve the activity of MDA,NOS,SOD,and decrease BPV in patients hypertensive patients with liver-yang hyperactivity syndrome.

关 键 词：高血压 松龄血脉康胶囊 苯磺酸氨氯地平 氧化应激 一氧化氮合酶 血压变异性 

分 类 号：R544.1[医药卫生—心血管疾病] R255.3[医药卫生—内科学]